Medication Precautions in the Instructions for Brigatinib/Brigatinib (Embry) Targeted Drug

Brigatinib/Brigatinib (Brigatinib), as an ALK-targeted drug, has clear descriptions of medication precautions in the instructions to help clinicians use it rationally. First, dose escalation is a major feature of brigatinib. It is generally recommended to use a lower dose initially and then increase to the recommended therapeutic dose after a week or so of observing tolerance. This design is based on considerations of the risk of adverse pulmonary reactions, especially early onset of pneumonia-like symptoms. Therefore, doctors should remind patients to pay close attention to respiratory symptoms when prescribing brigatinib, and promptly evaluate if cough, dyspnea, or imaging abnormalities occur.

Secondly, brigatinib may also have effects on the heart, electrolytes and blood pressure. The instructions recommend monitoring electrocardiogram and blood pressure levels before and during medication. For patients with underlying cardiac disease, brigatinib needs to be used with greater caution and dose adjustment if necessary. In addition, regular testing of liver function and creatine kinase levels is equally important, as brigatinib may impose a burden on liver metabolism and muscle health.

In terms of drug interactions, brigatinib is mainly metabolized byCYP3A4. The instructions remind you to avoid simultaneous use with strong CYP3A inhibitors or inducers to avoid fluctuations in drug concentration. When patients combine other treatments, doctors need to comprehensively evaluate the drug combination to avoid decreased efficacy or increased toxicity.

For special groups, the instructions state that the use of brigatinib is not recommended for pregnant and lactating women because it may cause potential risks to the fetus or infant. In addition, experience with pediatric patients is limited, so application in this population still requires caution. In elderly patients, monitoring and dose adjustment are required based on individual underlying diseases.

Reference materials:https://www.alunbrig.com/